Bruker's $66.54 close tops its September 30 peak by 2.76%, a new high for the stock, with the rest of the toolmaker group higher alongside it.
Moves: Nov 9, 2026 · Alpha Vantage daily close
13 more related stocks · 3 have no US listing
Headquartered in Waltham, MA Fiscal year ends December NYSE: TMO thermofisher.com
Thermo Fisher Scientific Inc. (NYSE: TMO) serves science globally with annual revenue exceeding $45 billion. The company enables customers to make the world healthier, cleaner and safer by supporting life sciences research, solving complex analytical challenges, increasing laboratory productivity, improving patient health through diagnostics, and aiding in the development and manufacture of life-changing therapies. Thermo Fisher delivers an extensive combination of innovative technologies, purchasing convenience and pharmaceutical services through its portfolio of brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Gibco, Fisher Scientific, Unity Lab Services, Patheon and PPD. The company operates through four reportable segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. Its product and service offerings span mass spectrometry, electron microscopy, genomic sequencing, proteomics, autoimmune diagnostics, laboratory distribution channels, pharmaceutical contract development and manufacturing, and clinical research services. Updated
Bruker's $66.54 close tops its September 30 peak by 2.76%, a new high for the stock, with the rest of the toolmaker group higher alongside it.
Moves: Nov 9, 2026 · Alpha Vantage daily close
13 more related stocks · 3 have no US listing
The leadership baton is being passed to second-tier data center names, and Cramer would rather own companies with clean balance sheets than the big caps issuing debt and equity to stay in the AI race. He is not calling a bottom yet: without a high-volume reversal day, he keeps money elsewhere.
Thermo Fisher just printed a fresh 52-week high at $704.15, 1.1% above the peak it set on October 15. The $260.6 billion name has now clawed back everything it lost from April's $447 low.
The bull case for data centers today rested on financing rather than profits, and Cramer wants to hear a customer say the chips are minting money before calling it clear. He expects Meta's at-the-market selling to weigh on the stock as supply hits at the wrong moments, with borrowing costs into a Fed decision the swing factor for everything levered to the buildout.
The call that matters for holders here is supply: Cramer argues the equity and debt markets are nearly tapped out after Meta, Alphabet and SpaceX raisings, with Anthropic's S1 now in line. He stops short of calling a top while pushing for buybacks and takeovers over further deals, favoring staged buying in Applied Materials and patience on Moderna.
An outsized 4.27% day for a life sciences giant, and it follows this morning's Q3 earnings beat. Keep an eye on whether the bid holds into the close.
A 4.25% jump to $694.47 follows this morning's Q3 earnings beat. The question now is whether life-science tools demand holds up past one quarter.
Demand across life-sciences tools is holding up: Thermo Fisher beat on both lines with adjusted operating margin widening 120 basis points to 24.5%. Updated full-year guidance lands on this morning's call, so keep an eye on the stock.
Twelve straight quarters of EPS beats go on the line at 6:00 AM ET, with consensus at $6.40 on $11.95 billion in revenue. The real tell is whether life-science tools and bioprocessing demand held up well enough to extend the run.
Thermo Fisher just set a 52-week high at $696.49, roughly 56% above its March low. The $257.6 billion life-science tools name has never been priced higher in the past year.
Jim Cramer just declared the companies that supply drug labs and research instruments the true heirs to the data center trade, and three stocks are already beating the NASDAQ-100 by a wide…
Pre-Market Stock Futures: Futures are trading lower as we get to wrap up a busy week, and what a week it has been. After a solid mid-week rally on Wednesday that had…
Stocks took a beating Tuesday as surging oil prices and looming inflation data rattled every corner of the market, and now Wall Street analysts are reshuffling their calls on names ranging from…
Clark Howard named a specific age when corporate America tends to push workers out, and it falls years before most people's retirement plans even begin to account for income gaps, portfolio shortfalls,…
Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names…
Agilent Technologies has a company-confirmed earnings report dropping after the close on August 26, and every operating lever heading into that date is pointing the same direction. Here is what retirement-focused investors…
Jefferies just named five U.S. dividend stocks to its exclusive Global Best Ideas list, and with the S&P 500 stretched to historically expensive valuations, the case for these high-conviction picks has never…
Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, and, as we mentioned before, it all depends on the status of the war with Iran and…
If a recession were to hit, it’s a foregone conclusion that people won’t stop taking their prescriptions, and they won’t cancel major medical treatments. The same can be said for people who…
Danaher (NYSE: DHR | DHR Price Prediction) and Thermo Fisher Scientific (NYSE: TMO) both reported Q3 2025 earnings showing revenue growth around 5%, but underlying business momentum tells very different stories. Danaher…
The Rise of a Frenzied Trading Style Cathie Wood, founder of ARK Invest, burst into investor consciousness in 2020 when her flagship ARK Innovation ETF (NYSEARCA:ARKK) soared 153%, fueled by bold bets…
With another 13F filing season out of the way, investors may wish to check out the names that the big money has been scooping up in recent months. In the first quarter,…
Daniel Loeb is a brilliant billionaire investor who’s invested in all sorts of market environments. Indeed, this isn’t the first time he’s encountered intense uncertainty and it probably won’t be the last.…
Thursday's top analyst upgrades and downgrades included American Airlines, Amgen, Block, Chewy, First Solar, Nvidia, Southwest Airlines, Taiwan Semiconductor Manufacturing and Toast.
Thursday's top analyst upgrades and downgrades included Airbnb, Apple, Bluebird Bio, Cinemark, Cisco Systems, Coinbase Global, Etsy, Lyft, Microsoft, QuantumScape, Redfin, Snowflake and Starbucks.
Thermo Fisher Scientific Inc. (NYSE: TMO) serves science globally with annual revenue exceeding $45 billion.
24/7 Wall St.'s 12-month price target for TMO is $797.88, rated Buy. The Wall Street consensus target is $756.52. TMO price prediction →